JP2024540319A5 - - Google Patents

Info

Publication number
JP2024540319A5
JP2024540319A5 JP2024526661A JP2024526661A JP2024540319A5 JP 2024540319 A5 JP2024540319 A5 JP 2024540319A5 JP 2024526661 A JP2024526661 A JP 2024526661A JP 2024526661 A JP2024526661 A JP 2024526661A JP 2024540319 A5 JP2024540319 A5 JP 2024540319A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
composition according
cftr
betamethasone
hyaluronic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024526661A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024540319A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2022/080807 external-priority patent/WO2023079072A1/en
Publication of JP2024540319A publication Critical patent/JP2024540319A/ja
Publication of JP2024540319A5 publication Critical patent/JP2024540319A5/ja
Pending legal-status Critical Current

Links

JP2024526661A 2021-11-05 2022-11-04 肺粘膜炎症の処置のための低分子量ヒアルロン酸の使用 Pending JP2024540319A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP21306554 2021-11-05
EP21306554.3 2021-11-05
PCT/EP2022/080807 WO2023079072A1 (en) 2021-11-05 2022-11-04 Use of low molecular weight hyaluronic acid for the treatment of lung mucosal inflammation

Publications (2)

Publication Number Publication Date
JP2024540319A JP2024540319A (ja) 2024-10-31
JP2024540319A5 true JP2024540319A5 (https=) 2025-09-16

Family

ID=78770564

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024526661A Pending JP2024540319A (ja) 2021-11-05 2022-11-04 肺粘膜炎症の処置のための低分子量ヒアルロン酸の使用

Country Status (3)

Country Link
EP (1) EP4426317A1 (https=)
JP (1) JP2024540319A (https=)
WO (1) WO2023079072A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12285541B2 (en) * 2023-01-26 2025-04-29 Insignia Pharmaceuticals, Llc Pharmaceutical compositions for treating osteoarthritis

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7060691B2 (en) * 2002-10-10 2006-06-13 Giuseppe Petrigni Pharmaceutical colloidal preparation useful in the treatment of respiratory diseases
FR2847818B1 (fr) 2002-11-28 2008-04-04 Agro Ind Rech S Et Dev Ard Composition pharmaceutique a base d'acide hyaluronique
FR2919185B1 (fr) 2007-07-23 2010-09-10 Ard Sa Utilisation d'acide hyaluronique pour la preparation de compositions destinees a l'amelioration notamment de l'etat des muqueuses
CN116515924A (zh) * 2014-04-16 2023-08-01 青岛惠诺德生物科技有限公司 一种生物活性透明质酸片段、其生产方法、应用、制剂及含有该制剂的物品
US20230172950A1 (en) * 2020-04-29 2023-06-08 Avm Biotechnology, Llc Glucocorticoid Receptor (GR) Modulators for Treating a SARS-COV-2 Virus
WO2022236585A1 (zh) * 2021-05-10 2022-11-17 傅毓秀 玻尿酸用于制备治疗肺纤维化药剂的用途

Similar Documents

Publication Publication Date Title
Edsbäcker et al. Do airway clearance mechanisms influence the local and systemic effects of inhaled corticosteroids?
US5192528A (en) Corticosteroid inhalation treatment method
JP2024540319A5 (https=)
JP2023530166A5 (https=)
Toogood High-dose inhaled steroid therapy for asthma
JP2017197569A5 (https=)
Saha et al. Growth of asthmatic children is slower during than before treatment with inhaled glucocorticoids
EP2923702A1 (en) Composition of cyclodextrin with budesonide derivatives for treatment and prevention of pulmonary inflammatory disease
JP2022507103A5 (https=)
Vance et al. Effects of particle size of inhaled corticosteroid on the voice
Lipworth Targets for inhaled treatment
Hatton et al. A comparison of ‘abruptly stopping’with ‘tailing off’oral corticosteroids in acute asthma
EDiGER et al. Clinical effectiveness of nebulised budesonide in the treatment of acute asthma attacks
JP2020536859A5 (https=)
Szefler A review of budesonide inhalation suspension in the treatment of pediatric asthma
Ververeli et al. Oral corticosteroid-sparing effects of inhaled corticosteroids in the treatment of persistent and acute asthma
EP4426317A1 (en) Use of low molecular weight hyaluronic acid for the treatment of lung mucosal inflammation
EP1073441A1 (en) Use of a glucocorticosteroid for the manufacture of a medicament for treating mild/early forms of copd (chronic obstructive pulmonary disease)
Bateman et al. Randomized comparison of ciclesonide 160 and 640 μg/day in severe asthma
Lipworth et al. High-dose inhaled steroids in asthmatic children
König Evidence for benefits of early intervention with non‐steroidal drugs in asthma
Smith et al. A controlled trial of beclomethasone dipropionate for asthma
JP2024513388A5 (https=)
Kondekar et al. To compare the efficacy of oral Deflazacort, oral prednisolone and inhaled Budesonide in the treatment of salbutamol refractory acute asthma in children
Escribano et al. Clinical comparability between the CFC and HFA budesonide pressurised metered-dose inhalers in paediatric patients with asthma: a randomised controlled trial